Beck Bode LLC’s Edwards Lifesciences EW Stock Holding History

Beck Bode LLC’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,200	Closed	-$24.5K	–	124
2026 Q1	$24.5K	Buy	+11,200	New	+$923K	﹤0.01%	95

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Beck Bode LLC's EW Position: Q1 2022 in Review

Beck Bode LLC sold out of Edwards Lifesciences (EW) in Q1 2022, closing a stake of 4,579 shares — an estimated $593K sold.

Beck Bode LLC first reported a position in EW in Q4 2018 and held it in 12 quarters. The position peaked at $15.2M in Q3 2020. 1,315 funds tracked by Wall St. Rank hold EW as of Q1 2022.

Beck Bode LLC reported no remaining Edwards Lifesciences position as of Q1 2022 after selling out during the quarter.
Beck Bode LLC sold 4,579 Edwards Lifesciences shares in Q1 2022, an estimated $593K.
Beck Bode LLC first reported a position in Edwards Lifesciences in Q4 2018 and held it in 12 quarters.
Beck Bode LLC's Edwards Lifesciences position peaked at $15.2M in Q3 2020.
1,315 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on Beck Bode LLC's 13F filing for Q1 2022, filed 2 May 2022.